BEGIN:VCALENDAR VERSION:2.0 METHOD:PUBLISH PRODID:-//Telerik Inc.//Sitefinity CMS 13.3//EN BEGIN:VTIMEZONE TZID:UTC BEGIN:STANDARD DTSTART;VALUE=DATE:20230101 TZNAME:UTC TZOFFSETFROM:+0000 TZOFFSETTO:+0000 END:STANDARD END:VTIMEZONE BEGIN:VEVENT DESCRIPTION:Joint PSI Pharmaceutical Statistics &\; DIA Statistics Commu nity \; DIA Chair: Susan Duke\, Manager\, Benefit Risk Evaluation\, GS K \; Speaker: Andreas Sashegyi\, Research Advisor\, Decision Sciences Lilly Corporate Center\, Lilly\nA Benefit-risk Model to Facilitate DMC-spo nsor Communication and Decision Making\nAndreas Sashegyi \nDrug Informatio n Journal\, Vol. 45\, pp. 749-757\, 2011 Abstract | Paper+ | Slides \nPSI Chair: Katherine Hutchinson\, Head of Consultancy\, Quanticate Speaker: S ara Hughes\, VP\, Clinical Statistics\, GSK \nInforming the selection of f utility stopping thresholds: case study from a late-phase clinical trial&n bsp\; \; \nSara Hughes\, Robert L. Cuffe\, Alfons Lieftucht and W. Gar rett Nichols \; \nPharmaceutical Statistics\, Vol. 8\, Issue 1\, pp. 2 5-37\, 2009 Abstract | Paper+ | Slides \; \nDiscussant: Lisa LaVange \, Director\, Office of Biostatistics in the Office of Translational Scien ces\, FDA + Papers available to view from 5th June 2012 to 3rd July 2012. For a flier advertising the event\, please click here.  \; DTEND:20120612T163000Z DTSTAMP:20240328T221640Z DTSTART:20120612T150000Z LOCATION: SEQUENCE:0 SUMMARY:Journal Club - Decision Making at Interims and DMCs (Joint DIA Even t) UID:RFCALITEM638472610007426577 X-ALT-DESC;FMTTYPE=text/html:
Joint PSI Pharmaceutical Statistics &\; DIA Statistics Community \;
DIA Chair: Susan D uke\, Manager\, Benefit Risk Evaluation\, GSK \;
Speake
r: Andreas Sashegyi\, Research Advisor\, Decision Sciences Lilly
Corporate Center\, Lilly
\nA Benefit-risk Model to Facilitate DMC-spo
nsor Communication and Decision Making
\nAndreas Sashegyi
\nDru
g Information Journal\, Vol. 45\, pp. 749-757\, 2011
Abstract | Paper+ | Slides
\nPSI Chair: Katherine Hutchinson\, Head of Consultancy\, Quanticate
Speaker: Sara Hughes\, VP\, Clinical Statistics\, GSK
\nInf
orming the selection of futility stopping thresholds: case study from a la
te-phase clinical trial \; \;
\nSara Hughes\, Robert L. Cuff
e\, Alfons Lieftucht and W. Garrett Nichols \;
\nPharmaceutical
Statistics\, Vol. 8\, Issue 1\, pp. 25-37\, 2009
Abstract | Paper+<
/sup> | Slides \;
\nDiscussant: Lisa LaVange\, Director\, Office of Biostati
stics in the Office of Translational Sciences\, FDA